TY - JOUR
T1 - Recombinant human thrombopoietin attenuates carboplatin-induced severe thrombocytopenia and the need for platelet transfusions in patients with gynecologic cancer
AU - Vadhan-Raj, Saroj
AU - Verschraegen, Claire F.
AU - Bueso-Ramos, Carlos
AU - Broxmeyer, Hal E.
AU - Kudelka, Andrzej P.
AU - Freedman, Ralph S.
AU - Edwards, Creighton L.
AU - Gershenson, David
AU - Jones, Dennie
AU - Ashby, Mark
AU - Kavanagh, John J.
PY - 2000/3/7
Y1 - 2000/3/7
N2 - Background: Thrombocytopenia is a significant problem in the treatment of cancer. Objective: To assess the clinical safety of therapy with recombinant human thrombopoietin (rhTPO) and its ability to ameliorate chemotherapy-induced severe thrombocytopenia. Design: Phase 1/11 clinical cohort study. Setting: The University of Texas M.D. Anderson Cancer Center, Houston, Texas. Patients: 29 patients with gynecologic cancer. Intervention: Recombinant human thrombopoietin was given before chemotherapy and after a second cycle of carboplatin therapy. Measurements: Peripheral blood counts and platelet transfusions. Results: Administration of rhTPO after chemotherapy significantly reduced the degree and duration of thrombocytopenia and enhanced platelet recovery. In patients who received the optimal biological dose of rhTPO (1.2 μg/kg of body weight) in cycle 2 (carboplatin plus rhTPO), the mean platelet count nadir was higher (44 x 109 cells/L and 20 x 109 cells/L;P = 0.002) and the duration of thrombocytopenia was shorter (days with a platelet count <20 x 109 cells/L, 1 and 4 [P = 0.002]; days with a platelet count <50 x 109 cells/L, 4 and 7 [P = 0.006]) than in cycle 1 (carboplatin only). The need for platelet transfusion in this group was reduced from 75% of patients in cycle 1 to 25% of patients in cycle 2 (P 0.013). Conclusions: Therapy with rhTPO seems to be safe and may attenuate chemotherapy-induced severe thrombocytopenia and reduce the need for platelet transfusions.
AB - Background: Thrombocytopenia is a significant problem in the treatment of cancer. Objective: To assess the clinical safety of therapy with recombinant human thrombopoietin (rhTPO) and its ability to ameliorate chemotherapy-induced severe thrombocytopenia. Design: Phase 1/11 clinical cohort study. Setting: The University of Texas M.D. Anderson Cancer Center, Houston, Texas. Patients: 29 patients with gynecologic cancer. Intervention: Recombinant human thrombopoietin was given before chemotherapy and after a second cycle of carboplatin therapy. Measurements: Peripheral blood counts and platelet transfusions. Results: Administration of rhTPO after chemotherapy significantly reduced the degree and duration of thrombocytopenia and enhanced platelet recovery. In patients who received the optimal biological dose of rhTPO (1.2 μg/kg of body weight) in cycle 2 (carboplatin plus rhTPO), the mean platelet count nadir was higher (44 x 109 cells/L and 20 x 109 cells/L;P = 0.002) and the duration of thrombocytopenia was shorter (days with a platelet count <20 x 109 cells/L, 1 and 4 [P = 0.002]; days with a platelet count <50 x 109 cells/L, 4 and 7 [P = 0.006]) than in cycle 1 (carboplatin only). The need for platelet transfusion in this group was reduced from 75% of patients in cycle 1 to 25% of patients in cycle 2 (P 0.013). Conclusions: Therapy with rhTPO seems to be safe and may attenuate chemotherapy-induced severe thrombocytopenia and reduce the need for platelet transfusions.
UR - http://www.scopus.com/inward/record.url?scp=0034050651&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0034050651&partnerID=8YFLogxK
U2 - 10.7326/0003-4819-132-5-200003070-00005
DO - 10.7326/0003-4819-132-5-200003070-00005
M3 - Article
C2 - 10691586
AN - SCOPUS:0034050651
SN - 0003-4819
VL - 132
SP - 364
EP - 368
JO - Annals of internal medicine
JF - Annals of internal medicine
IS - 5
ER -